Outcome measure
Axillary Sweating Daily Diary (ASDD)
The Axillary Sweating Daily Diary (ASDD) is a patient-reported instrument scored 0–10 and used as a primary endpoint in the ATMOS-1 and ATMOS-2 Phase 3 trials supporting Qbrexza (glycopyrronium tosylate).
- Type
- patient reported
- Scale
- 0 – 10
- Consumer-facing?
- No
- Primary use
- Qbrexza (ATMOS-1, ATMOS-2) primary endpoint
Daily-diary methodology
ASDD asks patients to score their worst sweating severity at the end of each day on a 0–10 scale. Daily entries are aggregated into weekly averages for trial endpoint analyses. The daily-diary structure captures variability and recency that single-timepoint recall instruments can miss.
Responder definitions
Trial responder definitions typically involve a ≥4-point improvement on ASDD from baseline at the primary endpoint timepoint. The ATMOS-1 and ATMOS-2 trials reported responder rates at week 4; specific values render through claim packets.
Reading paths
·Related references
Read related evidence.
Treatments scored with this measure